Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00038766 · ClinicalTrials.gov registry record · Phase 2
CNI-1493 for Treatment of Moderate to Severe Crohn's Disease
A Phase 2 study, sponsored by Ferring Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT00038766: Clinical Trial Phase 2 study, sponsored by Ferring Pharmaceuticals.
NCT00038766 is a Phase 2 study that was terminated before completion, run by Ferring Pharmaceuticals. The registered enrollment target is 33 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00038766, a Phase 2 study, was terminated before completion, sponsored by Ferring Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether CNI-1493 is safe and effective in the treatment of moderate to severe Crohn's Disease.
Interventions
- DRUG placebo
- DRUG semapimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2002-06 |
| Est. Completion | 2003-06 |
| Phase | Phase 2 |
Why NCT00038766 stopped before completion
NCT00038766 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00038766 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00038766 about?
NCT00038766 is a clinical study titled "CNI-1493 for Treatment of Moderate to Severe Crohn's Disease". The purpose of this study is to determine whether CNI-1493 is safe and effective in the treatment of moderate to severe Crohn's Disease.
What is the current status of trial NCT00038766?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2002-06. Estimated completion is 2003-06.
What interventions are being tested in trial NCT00038766?
The interventions under investigation include: placebo (DRUG), semapimod (DRUG).
Who is sponsoring clinical trial NCT00038766?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00038766's enrollment target sits among peer trials
33 1553rd of 2000 higher than 438 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia